U.S. Nonfarm Payrolls Increase by 50,000, Unemployment Rate Drops to 4.4%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Benzinga
- Labor Market Stability: According to the Bureau of Labor Statistics, nonfarm payrolls increased by 50,000 in December 2025, remaining largely unchanged from November's downwardly revised gain of 56,000, although slightly below the expected 60,000, indicating resilience in the labor market and easing concerns about rising unemployment.
- Unemployment Rate Decline: The unemployment rate fell from a revised 4.5% in November to 4.4%, landing below expectations of 4.5%, suggesting improvements in the labor market that could support consumer confidence and spending.
- Wage Growth Acceleration: Average hourly earnings rose by 0.3% month-over-month, accelerating from November's 0.2% increase and matching forecasts, which may drive consumer spending and bolster economic growth.
- Housing Market Slowdown: Housing starts declined by 4.6% from the previous month to an annualized rate of 1.246 million units, while building permits fell by 0.2% to an annualized rate of 1.412 million, indicating a slowdown in the real estate market that could impact the overall pace of economic recovery.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACON
Wall Street analysts forecast ACON stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.360
Low
23.00
Averages
23.00
High
23.00
Current: 3.360
Low
23.00
Averages
23.00
High
23.00
No data
About ACON
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aclarion Rejects Echo Lake's Acquisition Proposal
- Board Rejects Acquisition Proposal: Aclarion's Board unanimously rejected Echo Lake Capital's unsolicited acquisition proposal at $4 per share, asserting that it significantly undervalues the company's strategic potential and intrinsic value, indicating a disregard for shareholder interests.
- Acquisition Structure Concerns: The Board highlighted that Echo Lake's proposal would allow it to acquire Aclarion's cash and other valuable assets at a substantial discount, thereby harming the interests of other shareholders and reflecting an unreasonable proposal structure.
- Commitment to Value Creation: Aclarion's Board reiterated its commitment to pursuing credible paths for value creation and remains open to any proposals that appropriately reflect the company's intrinsic value, ensuring the interests of all shareholders are protected.
- Technological Background: Aclarion focuses on the chronic low back pain market, leveraging the Nociscan platform to assist physicians in identifying pain sources through magnetic resonance spectroscopy, showcasing the company's innovative capabilities and market potential in healthcare technology.
See More
Aclarion Stockholders Approve All Proposals at Annual Meeting
- Board Elections: At the 2026 Annual Meeting, Aclarion's stockholders elected seven directors, including CEO Brent Ness, to serve until 2027, reflecting strong shareholder confidence in the company's leadership.
- Audit Firm Appointment: Stockholders approved Haynie & Company as the company's independent registered public accounting firm, a decision that will enhance financial transparency and bolster investor confidence.
- Equity Incentive Plan Amendment: The amendment to the 2022 equity incentive plan aims to attract and retain key talent, thereby driving ongoing innovation and growth in the healthcare technology sector.
- Business Growth Highlights: Aclarion achieved a 196% year-over-year increase in Nociscan scan volumes in Q1 2026 and expanded insurance coverage in the UK, indicating robust growth momentum and market recognition in the chronic low back pain sector.
See More
Aclarion Expands Nociscan Availability in Los Angeles Area
- Partnership Agreement: Aclarion has signed an agreement with the Institute of Neuro Innovation in Los Angeles to introduce Nociscan, leveraging Dr. Amir Vokshoor's team to enhance precise treatment decisions for chronic low back pain patients, thereby improving treatment success rates.
- Data Asset Development: By integrating with SPECT-CT, Nociscan will facilitate a comparative study of chemical biomarker data and bone metabolic information, enhancing the accumulation of real-world evidence that supports payer and provider adoption, thus driving the company's growth strategy in the market.
- Market Demand Response: With approximately 266 million people globally affected by chronic low back pain, Aclarion's Nociscan platform serves as the first evidence-supported SaaS solution to noninvasively distinguish between painful and non-painful lumbar discs, addressing the urgent need for precise diagnostic tools in the market.
- Clinical Success Rate Improvement: Nociscan demonstrates a 97% surgical success rate when treating all Nociscan-positive discs, a significant metric that not only boosts physician confidence in treatment but also solidifies Aclarion's leadership position in the chronic low back pain market.
See More
Aclarion Study Reveals Immune Links to Back Pain
- Significant Research Findings: Aclarion's Nociscan technology successfully measured intradiscal propionic acid in an award-winning study, revealing immune-linked patient subtypes associated with back pain, indicating its potential value in chronic pain diagnosis.
- Expanded Clinical Applications: The study suggests that Nociscan may not only assist surgeons in identifying painful discs but also differentiate between mechanical, inflammatory, and immune-related pain sources, thereby advancing personalized treatment strategies.
- Immune Response Association: Findings indicate that elevated propionic acid levels correlate with specific immune activation patterns, particularly involving B-cell activation, suggesting that some back pain patients may be linked to immune responses rather than mere structural degeneration.
- Future Development Potential: Advances in Nociscan's technology may provide clinicians with deeper insights into the biological processes driving pain, opening new avenues for personalized spine care that enhance treatment outcomes and patient quality of life.
See More
Aclarion Responds to Echo Lake's Acquisition Proposal
- Acquisition Proposal Response: Aclarion has responded to Echo Lake Capital's acquisition offer of $4.00 per share, stating that the Board will carefully evaluate the proposal to ensure it aligns with the best interests of the company and all shareholders, thereby protecting shareholder value.
- Share Repurchase Program: The Board has authorized a share repurchase program, indicating a lack of confidence in the current market valuation, with plans to enhance shareholder value through buybacks while continuing to invest in business development to bolster long-term growth potential.
- Board Composition: Aclarion's Board consists of seven highly qualified directors with expertise in healthcare and technology investing, having appointed five new directors in the past six years to ensure diversity and alignment with strategic priorities, thus driving value creation for the company.
- Technological Innovation: Aclarion's Nociscan platform leverages Magnetic Resonance Spectroscopy and augmented intelligence algorithms to non-invasively assist physicians in identifying the sources of chronic low back pain, showcasing the company's innovative capabilities and market potential in the healthcare technology sector.
See More
Aclarion Partners with Weill Cornell for Lumbar Surgery Study
- Commercial Agreement Expansion: Aclarion Inc. has established a second commercial agreement with Weill Cornell Medicine to conduct a study on lumbar surgery for degenerative disc disease using its AI-driven platform Nociscan, showcasing the company's ongoing innovation in the healthcare sector.
- Technological Advantage: Nociscan combines artificial intelligence with magnetic resonance imaging to non-invasively identify painful discs in the lumbar spine, achieving a 97% success rate, thus providing an effective treatment option for chronic lower back pain affecting approximately 266 million people globally.
- Clear Research Objectives: The two-year prospective randomized study led by neurosurgeon Roger Hartl aims to deepen the understanding of degenerative disc disease's natural history, causes, and potential treatments, advancing medical knowledge in this area.
- Clinical Application Prospects: The study will evaluate the effectiveness of lumbar microdiscectomy surgery with or without a bone marrow aspirate concentrate injection on patient-reported outcomes, intervertebral disc health, and pain biomarkers, potentially providing crucial data to support future treatment options.
See More
Aclarion Rejects Echo Lake's Acquisition Proposal
- Board Rejects Acquisition Proposal: Aclarion's Board unanimously rejected Echo Lake Capital's unsolicited acquisition proposal at $4 per share, asserting that it significantly undervalues the company's strategic potential and intrinsic value, indicating a disregard for shareholder interests.
- Acquisition Structure Concerns: The Board highlighted that Echo Lake's proposal would allow it to acquire Aclarion's cash and other valuable assets at a substantial discount, thereby harming the interests of other shareholders and reflecting an unreasonable proposal structure.
- Commitment to Value Creation: Aclarion's Board reiterated its commitment to pursuing credible paths for value creation and remains open to any proposals that appropriately reflect the company's intrinsic value, ensuring the interests of all shareholders are protected.
- Technological Background: Aclarion focuses on the chronic low back pain market, leveraging the Nociscan platform to assist physicians in identifying pain sources through magnetic resonance spectroscopy, showcasing the company's innovative capabilities and market potential in healthcare technology.
See More
Aclarion Stockholders Approve All Proposals at Annual Meeting
- Board Elections: At the 2026 Annual Meeting, Aclarion's stockholders elected seven directors, including CEO Brent Ness, to serve until 2027, reflecting strong shareholder confidence in the company's leadership.
- Audit Firm Appointment: Stockholders approved Haynie & Company as the company's independent registered public accounting firm, a decision that will enhance financial transparency and bolster investor confidence.
- Equity Incentive Plan Amendment: The amendment to the 2022 equity incentive plan aims to attract and retain key talent, thereby driving ongoing innovation and growth in the healthcare technology sector.
- Business Growth Highlights: Aclarion achieved a 196% year-over-year increase in Nociscan scan volumes in Q1 2026 and expanded insurance coverage in the UK, indicating robust growth momentum and market recognition in the chronic low back pain sector.
See More
Aclarion Expands Nociscan Availability in Los Angeles Area
- Partnership Agreement: Aclarion has signed an agreement with the Institute of Neuro Innovation in Los Angeles to introduce Nociscan, leveraging Dr. Amir Vokshoor's team to enhance precise treatment decisions for chronic low back pain patients, thereby improving treatment success rates.
- Data Asset Development: By integrating with SPECT-CT, Nociscan will facilitate a comparative study of chemical biomarker data and bone metabolic information, enhancing the accumulation of real-world evidence that supports payer and provider adoption, thus driving the company's growth strategy in the market.
- Market Demand Response: With approximately 266 million people globally affected by chronic low back pain, Aclarion's Nociscan platform serves as the first evidence-supported SaaS solution to noninvasively distinguish between painful and non-painful lumbar discs, addressing the urgent need for precise diagnostic tools in the market.
- Clinical Success Rate Improvement: Nociscan demonstrates a 97% surgical success rate when treating all Nociscan-positive discs, a significant metric that not only boosts physician confidence in treatment but also solidifies Aclarion's leadership position in the chronic low back pain market.
See More
Aclarion Study Reveals Immune Links to Back Pain
- Significant Research Findings: Aclarion's Nociscan technology successfully measured intradiscal propionic acid in an award-winning study, revealing immune-linked patient subtypes associated with back pain, indicating its potential value in chronic pain diagnosis.
- Expanded Clinical Applications: The study suggests that Nociscan may not only assist surgeons in identifying painful discs but also differentiate between mechanical, inflammatory, and immune-related pain sources, thereby advancing personalized treatment strategies.
- Immune Response Association: Findings indicate that elevated propionic acid levels correlate with specific immune activation patterns, particularly involving B-cell activation, suggesting that some back pain patients may be linked to immune responses rather than mere structural degeneration.
- Future Development Potential: Advances in Nociscan's technology may provide clinicians with deeper insights into the biological processes driving pain, opening new avenues for personalized spine care that enhance treatment outcomes and patient quality of life.
See More
Aclarion Responds to Echo Lake's Acquisition Proposal
- Acquisition Proposal Response: Aclarion has responded to Echo Lake Capital's acquisition offer of $4.00 per share, stating that the Board will carefully evaluate the proposal to ensure it aligns with the best interests of the company and all shareholders, thereby protecting shareholder value.
- Share Repurchase Program: The Board has authorized a share repurchase program, indicating a lack of confidence in the current market valuation, with plans to enhance shareholder value through buybacks while continuing to invest in business development to bolster long-term growth potential.
- Board Composition: Aclarion's Board consists of seven highly qualified directors with expertise in healthcare and technology investing, having appointed five new directors in the past six years to ensure diversity and alignment with strategic priorities, thus driving value creation for the company.
- Technological Innovation: Aclarion's Nociscan platform leverages Magnetic Resonance Spectroscopy and augmented intelligence algorithms to non-invasively assist physicians in identifying the sources of chronic low back pain, showcasing the company's innovative capabilities and market potential in the healthcare technology sector.
See More
Aclarion Partners with Weill Cornell for Lumbar Surgery Study
- Commercial Agreement Expansion: Aclarion Inc. has established a second commercial agreement with Weill Cornell Medicine to conduct a study on lumbar surgery for degenerative disc disease using its AI-driven platform Nociscan, showcasing the company's ongoing innovation in the healthcare sector.
- Technological Advantage: Nociscan combines artificial intelligence with magnetic resonance imaging to non-invasively identify painful discs in the lumbar spine, achieving a 97% success rate, thus providing an effective treatment option for chronic lower back pain affecting approximately 266 million people globally.
- Clear Research Objectives: The two-year prospective randomized study led by neurosurgeon Roger Hartl aims to deepen the understanding of degenerative disc disease's natural history, causes, and potential treatments, advancing medical knowledge in this area.
- Clinical Application Prospects: The study will evaluate the effectiveness of lumbar microdiscectomy surgery with or without a bone marrow aspirate concentrate injection on patient-reported outcomes, intervertebral disc health, and pain biomarkers, potentially providing crucial data to support future treatment options.
See More
